» Articles » PMID: 32642729

New Insights into the Neurofibroma Tumor Cells of Origin

Overview
Journal Neurooncol Adv
Date 2020 Jul 10
PMID 32642729
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Neurofibromatosis type I (NF1) is a debilitating inherited tumor syndrome affecting around 1 in 3000 people. Patients present with a variety of tumors caused by biallelic loss of the tumor suppressor neurofibromin (NF1), a negative regulator of Ras signaling. While the mechanism of tumor formation is similar in the majority of NF1 cases, the clinical spectrum of tumors can vary depending on spatiotemporal loss of heterozygosity of in cells derived from the neural crest during development. The hallmark lesions that give NF1 its namesake are neurofibromas, which are benign Schwann cell tumors composed of nervous and fibrous tissue. Neurofibromas can be found in the skin (cutaneous neurofibroma) or deeper in body near nerve plexuses (plexiform neurofibroma). While neurofibromas have been known to be Schwann cell tumors for many years, the exact timing and initiating cell has remained elusive. This has led to difficulties in developing animal models and successful therapies for NF1. A culmination of recent genetic studies has finally begun to shed light on the detailed cellular origins of neurofibromatosis. In this review, we will examine the hunt for neurofibroma tumor cells of origin through a historical lens, detailing the genetic systems used to delineate the source of plexiform and cutaneous neurofibromas. Through these novel findings, we can better understand the cellular, temporal, and developmental context during tumor initiation. By leveraging this data, we hope to uncover new therapeutic targets and mechanisms to treat NF1 patients.

Citing Articles

Leveraging Neural Crest-Derived Tumors to Identify NF1 Cancer Stem Cell Signatures.

Khan S, Alson D, Sun L, Maloney C, Sun D Cancers (Basel). 2024; 16(21).

PMID: 39518076 PMC: 11545784. DOI: 10.3390/cancers16213639.


Neurofibroma Involving a Bifid Median Nerve in a Pediatric Patient: A Case Report.

Free B, Smith N, Payatakes A J Hand Surg Glob Online. 2024; 6(2):241-243.

PMID: 38903847 PMC: 11185877. DOI: 10.1016/j.jhsg.2023.12.001.


Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing.

Bhandarkar A, Bhandarkar S, Babovic-Vuksanovic D, Raghunathan A, Schwartz J, Spinner R J Neurooncol. 2024; 169(1):147-153.

PMID: 38739187 DOI: 10.1007/s11060-024-04711-5.


The +/- Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation.

White E, Rhodes S Cancers (Basel). 2024; 16(5).

PMID: 38473354 PMC: 10930863. DOI: 10.3390/cancers16050994.


Schwann cell derived pleiotrophin stimulates fibroblast for proliferation and excessive collagen deposition in plexiform neurofibroma.

Tian Z, Du Z, Bai G, Gong Q, You Y, Xu G Cancer Gene Ther. 2024; 31(4):627-640.

PMID: 38302728 DOI: 10.1038/s41417-024-00727-1.


References
1.
Saito H, Yoshida T, Yamazaki H, Suzuki N . Conditional N-rasG12V expression promotes manifestations of neurofibromatosis in a mouse model. Oncogene. 2007; 26(32):4714-9. DOI: 10.1038/sj.onc.1210250. View

2.
Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns D . Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell. 2008; 13(2):117-28. DOI: 10.1016/j.ccr.2008.01.002. View

3.
Spivakov M, Fisher A . Epigenetic signatures of stem-cell identity. Nat Rev Genet. 2007; 8(4):263-71. DOI: 10.1038/nrg2046. View

4.
Sheela S, Riccardi V, Ratner N . Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol. 1990; 111(2):645-53. PMC: 2116200. DOI: 10.1083/jcb.111.2.645. View

5.
Feinberg A, Ohlsson R, Henikoff S . The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2005; 7(1):21-33. DOI: 10.1038/nrg1748. View